AMH before IVF: what it predicts, what it does not, and why age still matters more

Anti-Müllerian hormone feels like a single fertility score. It is not. Its strongest use is narrower: forecasting ovarian response.

What AMH actually measures

AMH is produced by granulosa cells in small growing follicles. Broadly, higher concentrations tend to reflect a larger recruitable follicle pool and lower concentrations a smaller pool.

What it predicts reasonably well

• Expected response to gonadotropin stimulation
• Low egg-yield risk
• Excess-response/OHSS risk when high
• How a clinic may choose a starting stimulation dose

What it does not measure

AMH does not inspect egg chromosomes, fertilization competence, blastocyst formation, implantation potential, or embryo genetics.

Low AMH is not a pregnancy verdict

ASRM specifically cautions that extremely low AMH should not be used to refuse IVF. Low AMH predicts fewer eggs on average, not zero chance.

High AMH is not automatically better

High AMH can signal strong response, but also hyper-response risk. PCOS is one setting where AMH can be high while other reproductive issues remain.

AMH and age answer different questions

Why numbers can vary

Assays and units vary. Interpret AMH with age, AFC, prior response, surgery, and lab method rather than treating one number as immutable truth.

After a real IVF cycle

Actual ovarian response becomes more informative than screening markers. A poor response to appropriate stimulation is itself important clinical information.

Questions to ask

• What egg yield do you expect from my AMH and AFC?
• How does age change your interpretation?
• Does it change dose or trigger?
• Am I high risk for OHSS?

FAQ

AMH is a response forecast, not a fertility expiration date.

AMH and stimulation-dose planning

Clinics do not usually choose gonadotropin dose from AMH alone, but AMH can meaningfully influence whether a patient starts on a lower, middle, or higher stimulation dose. The goal is not to maximize estradiol or follicle count at any cost. It is to recruit an appropriate cohort while limiting poor response at one end and ovarian hyperstimulation at the other.

AMH after ovarian surgery

Prior ovarian cystectomy, especially surgery involving endometriomas, can reduce measured reserve. The number should be interpreted with operative history and AFC rather than treated as an unexplained laboratory event.

AMH and contraception

Hormonal contraception can alter ovarian-reserve measurements in some patients. If an AMH result seems discordant with the clinical picture, ask whether medication use or timing may matter before drawing conclusions.

What to do with a very low result

The practical response is usually a conversation about expected yield, cumulative-cycle strategy, age-related embryo probabilities, budget, and whether alternative family-building options should be discussed. It should not be a categorical statement that IVF is impossible.

How to use this information in a real IVF consultation

Bring the numbers from your own cycle and ask the clinician to interpret the pattern rather than discussing the topic abstractly. IVF decisions become much clearer when the conversation moves from “What does this test mean?” to “What did this test and my last cycle together teach us about the next cycle?”

Ask what would actually change because of the finding: protocol, dose, trigger, fertilization method, culture strategy, transfer timing, genetic counseling, or nothing. If a test or label does not change management, understand why it is being ordered.

Keep the treatment funnel visible

Egg count, maturity, fertilization, blastocyst formation, genetic status, transfer, implantation, and live birth are different checkpoints. A strong result at one checkpoint improves opportunity but never guarantees success at the next. Good counseling keeps those denominators separate.

What this result should not be allowed to do

One laboratory value, one embryo label, or one disappointing cycle should not collapse the entire treatment conversation into a single verdict. Fertility treatment is probabilistic. The value of a result is in how it changes the next decision, not in how dramatic the number sounds on a portal screen.

Ask the clinic to separate three things explicitly: what is known from your data, what is inferred from population averages, and what remains uncertain. That distinction is especially important when a recommendation carries additional cost, another invasive procedure, embryo-disposition consequences, or an unproven add-on.

What a good second opinion should review

• The raw cycle numbers rather than only the final outcome
• Medication doses and stimulation timeline
• Trigger type and timing where relevant
• Egg maturity and fertilization counts
• Day-by-day embryo development
• Genetic-testing reports where applicable
• Transfer preparation and procedure notes
• Prior uterine/sperm evaluation that could change management

A second opinion is most useful when the new clinician can see the same underlying data as the first clinic. Otherwise you are comparing interpretations built from different information.

How to compare clinics on this topic

Ask how the program tracks its own outcomes for patients with a similar age, diagnosis, and cycle pattern. A good laboratory or fertility program should be able to explain its process without pretending that one protocol, grading system, or add-on works for everyone. Specificity is more useful than superlatives.

Decision checkpoint before the next cycle

Before another stimulation, retrieval, biopsy, or transfer begins, write down the one or two decisions this information is supposed to change. Examples include changing starting dose, changing trigger strategy, choosing conventional insemination versus ICSI, altering culture strategy, choosing a different FET preparation, seeking genetics counseling, or deciding that no change is justified. This prevents retrospective data from becoming expensive trivia.

Then ask what result would make the clinic reverse course. A treatment plan is more credible when the clinician can describe both the reason to use it and the finding that would make them stop using it.

Keep cumulative outcomes separate from per-step percentages

Fertility statistics are easy to make sound better by changing denominators. Fertilization rate is per mature oocyte, blastocyst rate can be reported per fertilized egg or per embryo still in culture, implantation is per transfer, and live birth can be per transfer, per retrieval, or cumulative across a complete egg cohort. When a clinic gives you a percentage, ask for the denominator.

For patients planning more than one retrieval or more than one frozen transfer, cumulative chance across the entire cohort can be more meaningful than the best-looking single-transfer statistic. That is also why avoiding unnecessary embryo discard, unnecessary cycle cancellation, and unsupported add-ons can matter to the overall strategy.